key: cord-0879698-dyy4ro1p
authors: Dolscheid‐Pommerich, Ramona; Bartok, Eva; Renn, Marcel; Kümmerer, Beate M.; Schulte, Bianca; Schmithausen, Ricarda M.; Stoffel‐Wagner, Birgit; Streeck, Hendrik; Saschenbrecker, Sandra; Steinhagen, Katja; Hartmann, Gunther
title: Correlation between a quantitative anti‐SARS‐CoV‐2 IgG ELISA and neutralization activity
date: 2021-08-31
journal: J Med Virol
DOI: 10.1002/jmv.27287
sha: 33ce2a8573072bcd5762252cc633b5132d141cbe
doc_id: 879698
cord_uid: dyy4ro1p

In the current COVID‐19 pandemic, a better understanding of the relationship between merely binding and functionally neutralizing antibodies is necessary to characterize protective antiviral immunity following infection or vaccination. This study analyzes the level of correlation between the novel quantitative EUROIMMUN Anti‐SARS‐CoV‐2 QuantiVac ELISA (IgG) and a microneutralization assay. A panel of 123 plasma samples from a COVID‐19 outbreak study population, preselected by semiquantitative anti‐SARS‐CoV‐2 IgG testing, was used to assess the relationship between the novel quantitative ELISA (IgG) and a microneutralization assay. Binding IgG targeting the S1 antigen was detected in 106 (86.2%) samples using the QuantiVac ELISA, while 89 (72.4%) samples showed neutralizing antibody activity. Spearman's correlation analysis demonstrated a strong positive relationship between anti‐S1 IgG levels and neutralizing antibody titers (r (s )= 0.819, p < 0.0001). High and low anti‐S1 IgG levels were associated with a positive predictive value of 72.0% for high‐titer neutralizing antibodies and a negative predictive value of 90.8% for low‐titer neutralizing antibodies, respectively. These results substantiate the implementation of the QuantiVac ELISA to assess protective immunity following infection or vaccination.

plasma samples from a COVID-19 outbreak study population, preselected by semiquantitative anti-SARS-CoV-2 IgG testing, was used to assess the relationship between the novel quantitative ELISA (IgG) and a microneutralization assay. Binding IgG targeting the S1 antigen was detected in 106 (86.2%) samples using the Quan-tiVac ELISA, while 89 (72.4%) samples showed neutralizing antibody activity. Spear-man´s correlation analysis demonstrated a strong positive relationship between anti-S1 IgG levels and neutralizing antibody titers (r s = 0.819, p < 0.0001). High and low anti-S1 IgG levels were associated with a positive predictive value of 72.0% for hightiter neutralizing antibodies and a negative predictive value of 90.8% for low-titer neutralizing antibodies, respectively. These results substantiate the implementation of the QuantiVac ELISA to assess protective immunity following infection or vaccination. 

In the current COVID-19 pandemic, the development of validated, standardized serological assays that quantitatively assess the antibody response against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is of crucial importance. These assays serve multiple purposes, including the quantification of antibodies against SARS-CoV-2, the collection of data for epidemiological surveillance and control, postvaccination monitoring, or the screening of recovered COVID-19 patients for convalescent plasma therapy. [1] [2] [3] The formation of SARS-CoV-2-specific antibodies that effectively reduce virulence/pathogenicity is likely to be crucial for the development of population immunity, which in turn is a major prerequisite to halt the COVID-19 pandemic. 4, 5 For the determination of neutralizing activity in This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. © 2021 The Authors. Journal of Medical Virology Published by Wiley Periodicals LLC

The EUROIMMUN Anti-SARS-CoV-2 QuantiVac ELISA (IgG), hereafter referred to as QuantiVac ELISA, was processed on the EUROIMMUN Analyzer I platform according to the manufacturer's instructions. The ELISA is based on 96-well microplates coated with the SARS-CoV-2 S1 domain (including RBD) expressed recombinantly in the human cell line HEK293 (ATCC). The data sheet reports no cross-reactivities with samples from patients infected with SARS-CoV-1, HCoV-229E, or HCoV-OC43. 14 Quantification of S1specific IgG was performed using a 6-point calibration curve covering a range from 1 to 120 relative units (RU)/ml. Samples yielding results above this analytical range were re-evaluated at a higher dilution.

Positive and negative controls were included in each test run. By multiplication with factor 3.2, results in RU/ml were converted into standardized binding antibody units (BAU)/ml. Results <25.6 were considered negative, ≥25.6 to <35.2 borderline, and ≥35.2 positive.

Microneutralization assays were performed as previously described 13 using a SARS-CoV-2 strain (SARS-CoV-2/human/Germany/Heinsberg- 

Confidence intervals (95% CI) were calculated according to the modified Wald method. Interassay concordance was assessed using the percentage of agreement and Kappa statistics, considering borderline results as positive. Cohen's kappa coefficient was calculated using the formula Kappa(ĸ) = (P 0 -P e )/(1 -P e ), where P 0 is the relative observed agreement, and P e is the hypothetical probability of random agreement. Kappa values of 0-0.20, 0.21-0.40, 0.41-0.60, 0.61-0.80, and 0.81-1.00 indicate poor, fair, moderate, good, and very good agreement, respectively. 16 Spearman rank-order correlation analysis was performed to evaluate the relationship between two assays. The unpaired Student's t test was used to identify significant differences between the means of the two groups. p values of less than 0.05 were considered statistically significant. Statistical analyses were conducted using GraphPad Prism version 6, GraphPad QuickCalcs (GraphPad Software, Inc.), and SigmaPlot 13.0 (SSI).

In 123 plasma samples that had been precharacterized as SARS-CoV-2 seropositive by semiquantitative IgG testing, anti-SARS-CoV-2 S1

IgG levels were measured quantitatively using the QuantiVac ELISA.

This resulted in values between <3.2 and 9881.6 BAU/ml with a mean ± standard deviation (SD) of 432.8 ± 1058.2 BAU/ml (median, 125.9 BAU/ml; interquartile range [IQR], 47.6-315.7 BAU/ml). Titers of neutralizing antibodies were determined by CPE reduction NT assay, ranging between <1.7 and 286 with a mean ± SD of 11.4 ± 33.6 (median, 3.5; IQR, 0-9.0).

Using the QuantiVac ELISA, 96 out of 123 samples were classified as positive, 10 as borderline, and 17 as negative. The CPE reduction NT assay yielded positive, borderline, and negative results in 68, 21, and 34 out of 123 cases, respectively (Table 1) . Thus, if borderline results were considered positive, the sensitivity of the QuantiVac ELISA amounted to 86.2% (106/123) and that of the CPE reduction NT assay to 72.4% (89/123).

All 89 samples testing positive or borderline by CPE reduction NT assay were also anti-S1 IgG positive or borderline by QuantiVac ELISA, corresponding to a positive agreement rate of 100% (89/89).

Among 34 neutralization-negative samples, 17 were negative for anti-S1 IgG by QuantiVac ELISA, resulting in a negative agreement rate of 50%. Accordingly, the overall agreement between the two assays amounted to 86.2% based on the correlation of positive and negative results in 106/123 cases. To correct the agreement for the probability of random coincidence, the Kappa coefficient was calculated (ĸ = 0.591) and indicated moderate agreement (Table 1) .

Spearman rank-order correlation analysis revealed a strong positive, statistically significant association between the quantitative levels of anti-SARS-CoV-2 S1 IgG and the titers of neutralizing antibodies (r s = 0.819, p < 0.0001; Figure 1 ).

To substantiate the calculated correlation, samples were assigned to two groups: high anti-SARS-CoV-2 S1 IgG (≥480 BAU/ml, n = 25) and low anti-SARS-CoV-2 S1 IgG (<480 BAU/ml, n = 98).

Comparison of the two groups revealed a significant difference between the mean neutralization titers (34.4 vs. 5.5, p < 0.0001).

Median titers were 18.0 (IQR, 9.0-22.0) and 2.2 (IQR, 0-4.5) in the high and low groups, respectively. The positive predictive value (PPV) of high anti-S1 IgG for the presence of high-titer (≥10) neutralizing antibodies was 72.0% (52.2%-85.9%), whereas low anti-S1 IgG levels were associated with a negative predictive value (NPV) of 90.8% (83.3%-95.3% for low-titer (<10) neutralizing antibodies.

Conventional neutralization assays are unsuitable for large-scale routine testing in the current COVID-19 pandemic. This has raised the question as to whether there are standardized and scalable serological assays that show a degree of correlation allowing estimates on neutralizing activity to assess immunity to reinfection and to support vaccination programs or antibody-based therapeutic trials.

T A B L E 1 Agreement between quantitative ELISA and microneutralization assay in 123 plasma samples obtained from inhabitants of a German community after a local SARS-CoV-2 super-spreading event F I G U R E 1 Correlation between quantitative ELISA and microneutralization assay. Binding anti-SARS-CoV-2 S1 IgG was determined quantitatively using the QuantiVac ELISA and titers of neutralizing antibodies were determined using the CPE reduction NT assay (n = 123). Neutralization titers correspond to reciprocal plasma dilutions protecting 50% of the wells at incubation with 100 TCID 50 of SARS-CoV-2. Samples with a cytopathic effect (CPE) equal or similar to the negative control are depicted on the y-axis. Dotted and dashed lines indicate borderline and positivity cut-offs, respectively. r s , Spearman rank-order correlation coefficient

To the best of our knowledge, this is the second study presenting the level of correlation between quantitative anti-S1 IgG levels determined by the EUROIMMUN QuantiVac ELISA and titers of neutralizing antibodies measured by a microneutralization assay.

The positive, negative, and overall qualitative agreement between both assays were 100%, 50%, and 86.2%, respectively, while the kappa value indicated moderate agreement (ĸ = 0.591). In addition, the quantitative results revealed a strong correlation (r s = 0.819), which was confirmed by high PPV (72.0%) and NPV (90.8%) results.

Rubio-Acero et al. 17 were first to report the performance of two quantitative anti-S1 assays, namely the QuantiVac ELISA The primary semiquantitative EUROIMMUN Anti-SARS-CoV-2 ELISA IgG was also analyzed by other groups, indicating a high correlation with neutralization activity (r s , 0.75-0.88). 9, 11, 18 In this semiquantitative ELISA, the same S1 antigen is coated on the microplate wells as in the QuantiVac ELISA, giving a possible explanation for the similarly high degree of correlation observed in the present study.

The strong correlation of the QuantiVac ELISA with neutralization testing suggests a high potential to quantitatively predict neutralizing antibody titers. However, the QuantiVac ELISA results are not a 100% correlate of the CPE reduction NT assay, and it has to be considered that a part of neutralization potency seems to be mediated by S-specific IgM antibodies. 19 

Data are available on request from the authors.

Ramona Dolscheid-Pommerich https://orcid.org/0000-0002-

Serology assays to manage COVID-19

Serological approaches for COVID-19: Epidemiologic perspective on surveillance and control

The role of antibody testing for SARS-CoV-2: is there one?

Potently neutralizing and protective human antibodies against SARS-CoV-2

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

Humoral responses and serological assays in SARS-CoV-2 infections

Development of diagnostic tests for detection of SARS-CoV-2

Serological assays estimate highly variable SARS-CoV-2 neutralizing antibody activity in recovered COVID-19 patients

Disease severity, fever, age, and sex correlate with SARS-CoV-2 neutralizing antibody responses

SARS coronavirus-2 microneutralisation and commercial serological assays correlated closely for some but not all enzyme immunoassays

Quantification of SARS-CoV-2 antibodies with eight commercially available immunoassays

Independent side-by-side validation and comparison of 4 serological platforms for SARS-CoV-2 antibody testing

Infection fatality rate of SARS-CoV2 in a super-spreading event in Germany

Package Insert

Determination of 50% endpoint titer using a simple formula

Practical Statistics for Medical Research. London: Chapman & Hall

In search of the SARS-CoV-2 protection correlate: head-to-head comparison of two quantitative S1 assays in pre-characterized oligo-/asymptomatic patients

Convalescent plasma therapy for the treatment of patients with COVID-19: assessment of methods available for antibody detection and their correlation with neutralising antibody levels

Cross-sectional evaluation of humoral responses against SARS-CoV-2 spike

Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2

Role of immunoglobulin M and A antibodies in the neutralization of severe acute respiratory syndrome coronavirus 2

Correlation between a quantitative anti-SARS-CoV-2 IgG ELISA and neutralization activity